Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment

@article{Klitgaard2016BrivaracetamRF,
  title={Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment},
  author={H. Klitgaard and A. Matagne and J. Nicolas and M. Gillard and Y. Lamberty and M. de Ryck and R. Kaminski and K. Leclercq and I. Niespodziany and Christian Wolff and M. Wood and J. Hannestad and Sophie Kervyn and B. Kenda},
  journal={Epilepsia},
  year={2016},
  volume={57}
}
Despite availability of effective antiepileptic drugs (AEDs), many patients with epilepsy continue to experience refractory seizures and adverse events. Achievement of better seizure control and fewer side effects is key to improving quality of life. This review describes the rationale for the discovery and preclinical profile of brivaracetam (BRV), currently under regulatory review as adjunctive therapy for adults with partial‐onset seizures. The discovery of BRV was triggered by the novel… Expand
Brivaracetam for the treatment of focal-onset seizures: pharmacokinetic and pharmacodynamic evaluations
TLDR
BRV is a high affinity synaptic vesicle glycoprotein 2A ligand, with 15–30-fold higher affinity than levetiracetam, that has a low potential for clinically relevant drug–drug interactions and may be associated with fewer clinical adverse effects. Expand
The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy
TLDR
The preclinical and clinical profile suggest that BRV is potentially an ideal compound in the emergency setting given the rapid onset of action associated with being water soluble and, therefore, available in intravenous formulation. Expand
Brivaracetam in the treatment of epilepsy: a review of clinical trial data
  • A. Feyissa
  • Medicine
  • Neuropsychiatric disease and treatment
  • 2019
TLDR
Examination of regulatory trials, post-marketing studies, and indirect comparison meta-analyses demonstrated equivalent efficacy and better tolerability of BRV when compared to other antiseizure drugs, appearing to suggest that behavioral adverse events are likely to be less frequent and less severe with BRV than LEV. Expand
A review of the pharmacology and clinical efficacy of brivaracetam
TLDR
BRV is highly effective in patients experiencing secondarily generalized tonic–clonic seizures, and safety data to date suggest a favorable psychiatric adverse effect profile in controlled studies, although limited postmarketing data are available. Expand
Brivaracetam: a novel antiepileptic drug for focal-onset seizures
TLDR
The efficacy and tolerability of adjunctive BRV in adults with focal-onset seizures have been explored in six randomized, placebo-controlled studies and showed significant efficacy outcomes for doses of 50–200 mg/day. Expand
Evaluation of brivaracetam: a new drug to treat epilepsy
TLDR
BVR is effective as adjunctive therapy for uncontrolled partial-onset seizures with or without secondary generalization in patients 16 years and older with epilepsy and reduces baseline-adjusted focal seizure frequency per week from 7.3 to 12.8% over placebo. Expand
Brivaracetam efficacy and safety in focal epilepsy
TLDR
There was no added benefit when BRV was used adjunctively with LEV in clinical trials, however, post-marketing data suggest that some patients may experience improved seizure control when switching from LEV. Expand
Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience
TLDR
This review summarizes the essential preclinical and clinical data of LEV and BRV that is currently available and includes the experiences at a large tertiary referral epilepsy center. Expand
Evaluation of brivaracetam efficacy as monotherapy in adult patients with focal seizures
TLDR
It is suggested that brivaracetam can be used as monotherapy without dose modifications, and in the absence of other AEDs, only marginal changes in the overall dose-response relationship would be expected. Expand
Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study
TLDR
A post-hoc analysis of data from three Phase III studies of adults with focal seizures taking 1-2 AEDs who received placebo or BRV 50-200mg/day without titration indicates that previous treatment failure with LEV does not preclude the use of BRV in patients with epilepsy. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 95 REFERENCES
Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam.
TLDR
One new AED with potential antiepileptogenic properties is levetiracetam, which was discovered using non-conventional drug screens, and markedly suppresses kindling development at doses devoid of adverse effects, with persistent suppression of kindled seizures even after termination of treatment. Expand
Mechanisms of Action of Levetiracetam and Newer SV2A Ligands
Publisher Summary This chapter describes the epilepsy pharmacology and reviews the mechanisms of action of levetiracetam (LEV), brivaracetam (BRV), and seletracetam (SEL). LEV is the (S)-enantiomerExpand
The Potential of Antiseizure Drugs and Agents that Act on Novel Molecular Targets as Antiepileptogenic Treatments
TLDR
Evidence largely from preclinical models for the antiepileptogenic activity of a diverse range of potential therapies, including some marketed antiseizure drugs, as well as agents that act by immune and inflammatory mechanisms are considered. Expand
Levetiracetam: the first SV2A ligand for the treatment of epilepsy
TLDR
The history of levetiracetam proves that a small core group of committed scientists and physicians, who dare to challenge the conventional scientific doctrine, can be successful in bringing to market a truly novel therapy for epilepsy patients. Expand
Levetiracetam: The Preclinical Profile of a New Class of Antiepileptic Drugs?
TLDR
A unique preclinical profile of levetiracetam is revealed, distinct from that of all known AEDs, suggesting that levetIRacetam could represent the first agent in a new class of AED's, and may possess antiepileptogenic properties. Expand
Targeting SV2A for discovery of antiepileptic drugs
Levetiracetam’s (Keppra) binding site and its subsequent identification as the synaptic vesicle protein 2A (SV2A) enabled the discovery of high affinity SV2A ligands with promising anticonvulsantExpand
Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy.
TLDR
The results suggest that levetiracetam may offer an effective, broad-spectrum treatment of epileptic seizures in patients, with a minimum of adverse effects, as compared with existing antiepileptic drugs. Expand
Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity.
TLDR
The pharmacological studies from this group led to the selection of (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide 83alpha (ucb 34714) as the most interesting candidate, approximately 10 times more potent than 2 as an antiseizure agent in audiogenic seizure-prone mice. Expand
SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy
TLDR
The concept that SV2A protein is an important target for both partial and generalized epilepsies and thereby relevant for the generation of new antiepileptic drugs with potential broad-spectrum efficacy is supported. Expand
Kindling Increases the Sensitivity of Rats to Adverse Effects of Certain Antiepileptic Drugs
TLDR
The data indicate that epileptogenesis induced by kindling renders the brain more susceptible to certain AE of AEDs, which should be avoided to avoid overestimation of the therapeutic index. Expand
...
1
2
3
4
5
...